Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States

Purpose: Antipsychotic (AP) medication adherence is important for the management of schizophrenia. This study thus aimed to evaluate prescriber- and patient-level characteristics and long-acting injectable (LAI) treatment use among patients with schizophrenia to determine the association between these factors and AP adherence. Patients and methods: Adult patients with schizophrenia in the United States were identified from Komodo Research Data (01/01/2016-06/30/2023). Patients were required to have been initiated on an oral or LAI AP (index date) during the intake period (07/01/2021-06/30/2022), by a provider who prescribed APs to ≥6 patients with schizophrenia over the intake period (index prescriber). Providers were characterized using quartiles of the proportion of LAIs over all APs prescribed during the intake period (non-LAI prescribers; Q1: low, ≤8.5% LAIs; Q2-3: intermediate, >8.5% and